Health

The formulation has the medicinal herb Bergenia ciliata, which can help ease pain in rheumatoid arthritis

A day after World Health Organisation(WHO) granted emergency use approval for Bharat Biotech’s COVID-19 vaccine Covaxin, an official of the US Centers for Disease Control and Prevention (CDC) has informed that all travellers fully vaccinated against COVID-19 with Covaxin have been given the green light to enter the United States from November 8.

Covaxin was also reviewed by WHO’s Strategic Advisory Group of Experts on Immunization (SAGE), and recommended its use in two doses, with a dose interval of four weeks, in all age groups 18 and above.

The Australian government on Monday gave recognition to Bharat Biotech’s Covaxin COVID-19 vaccine for the purpose of establishing a traveller’s vaccination status in the country.

India will produce over five billion doses of Covid vaccines for the country and the world by the end of 2022, Prime Minister Narendra Modi announced on Saturday at the G-20 Summit in Rome, where the grouping met to discuss, among other issues, developments related to the global pandemic.

India’s testing capacity has been ramped up extensively and it has conducted 60,58,85,769 COVID-19 tests so far, according to the Indian Council of Medical Research (ICMR) said on Friday.

In the new study, researchers at the National Institute of Mental Health and Neurological Sciences (NIMHANS), Bengaluru, and Institute of Genomics at the University of Tartu, Estonia, explored these aspects through the genetic analysis of individuals from families who have multiple affected members, considering that the increased prevalence of illness in a particular family should point to even more extreme evidence of the risky alleles.

As per the Research and Information System for Developing Countries (RIS) report, despite a slump in economic activity in 2020 due to the pandemic, the industry is projected to reach US$ 20.6 billion in 2021 and US$ 23.3 billion in 2022. In terms of global share, India has grown faster in the AYUSH market as compared to the world and accounts for about 2.8 per cent of the market, which is likely to hold even though disruptions in production are not ruled out.

In a new study, researchers at the Department of Biotechnology’s Bhubaneswar-based Institute of Life Sciences, (DBT-ILS) have investigated the potential for using a set of protein molecules called Mucins for developing such double network systems in combination with polymers.